Loading clinical trials...

Brentuximab for Newly Diagnosed Hodgkin Disease | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Brentuximab for Newly Diagnosed Hodgkin Disease

A Pilot Study of Risk Adapted Therapy Utilizing Upfront Brentuximab With Combination Chemotherapy in the Treatment of Children, Adolescents and Young Adults With Newly Diagnosed Hodgkin Lymphoma

NCT02398240•Mitchell Cairo

View on ClinicalTrials.gov

Summary

The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).

Eligibility

Age

1 - 29 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Normal Serum creatinine based on age or creatinine clearance \>60 ml/min/1.73 m2 or an equivalent radioisotope glomerular filtration rate (GFR) as determined by the institutional normal range.
•Direct bilirubin \< 1.5 upper limit of normal (ULN) for age, and SGOT (AST) or SGPT (ALT) \<3 x ULN
•Shortening fraction \>27% by echocardiogram, or
•Ejection fraction of \>50% by radionuclide angiogram or echocardiogram.
•For patients age 1-16 years, Lansky score of ≥60.
•For patients \> 16 years, Karnofsky score of ≥60.
•No prior Hodgkin lymphoma directed therapy is allowed except for emergent mediastinal irradiation (\<1000cGy) for superior vena cava (SVC) syndrome.

Exclusion Criteria

•Females who are pregnant (positive HCG) or lactating.
•Karnofsky \<60% or Lansky \<60% if less than 16 years of age.
•Age ≤1 year or \>29.99 years of age.

Locations (1)

New York Medical College

Valhalla, New York, United States

Key Dates

Start Date

May 1, 2015

Primary Completion Date

June 1, 2022

Completion Date

December 1, 2022

Last Updated

October 26, 2023

Enrollment

ESTIMATED participants

Conditions

Hodgkin Lymphoma

Interventions

Brentuximab Vedotin

DRUG

Doxorubicin

DRUG

Vincristine

DRUG

Rituximab

DRUG

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069

Mantle Cell LymphomaNon Hodgkin Lymphoma+1 more

View study

RECRUITINGPHASE1

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

NCT06189391

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 26, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Brentuximab for Newly Diagnosed Hodgkin Disease

Inclusion Criteria

Exclusion Criteria

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma